{"created":"2023-05-15T09:06:18.039954+00:00","id":12940,"links":{},"metadata":{"_buckets":{"deposit":"be01b127-8374-43f4-9c7e-d3834dca0363"},"_deposit":{"created_by":14,"id":"12940","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"12940"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00012940","sets":["1875:1978:1986"]},"author_link":["19174"],"item_2_alternative_title_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Molecular targeted cancer therapy: new roles for pathologists"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-10-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"51","bibliographicPageStart":"43","bibliographicVolumeNumber":"72","bibliographic_titles":[{"bibliographic_title":"市立札幌病院医誌 = Acta medica nosocomi Sapporo = The Journal of Sapporo City General Hospital"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"多くのがんで分子標的療法が日常的に行われるようになり、病理診断が分子標的治療対象患者の選択に重要な役割を果たすようになってきている。乳癌ではホルモン受容体やHER2の発現の有無、細胞増殖能といった病理標本で明らかとなる、がんの生物学的性質に基づき薬物療法が決定されるようになってきている。肺癌ではEGFR阻害剤やペメトレキセド、ベバシツマブなど腺癌で有効な薬剤があり、病理診断で非小細胞癌の中の腺癌と扁平上皮癌をより厳密に区別する必要性が増してきている。また、肺癌では2007年にEML4-ALK融合遺伝子陽性のALK肺癌が発見された。ALK阻害剤が有効なこの特殊な肺癌のスクリーニングには、高感度なALK免疫染色が有用とされる。胃癌、大腸癌、GISTなどの消化管がんでは、HER2、EGFR、c-kitの発現を病理標本で確認することで、分子標的治療の適応を決めている。本稿では分子標的治療と病理診断の関わりについて、最近の知見と当科での経験を合わせて述べたい。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立札幌病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0288-6073","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"辻, 隆裕"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"l425672143.pdf","filesize":[{"value":"2.2 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"l425672143.pdf","url":"https://sapmed.repo.nii.ac.jp/record/12940/files/l425672143.pdf"},"version_id":"1b22e2e3-b753-4cc0-a8ce-12a22184e0d0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"分子標的療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"病理診断","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫染色","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"分子標的療法と病理診断（特集分子標的薬を用いた治療戦略）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"分子標的療法と病理診断（特集分子標的薬を用いた治療戦略）","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1986"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-05-15"},"publish_date":"2014-05-15","publish_status":"0","recid":"12940","relation_version_is_last":true,"title":["分子標的療法と病理診断（特集分子標的薬を用いた治療戦略）"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T04:30:17.690508+00:00"}